-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces EURneffy Recommended for Approval by CHMP
-
-
-
-
-
-
-
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
-
-
-
-
-
-
-
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Closes Merger with Silverback Therapeutics (SBTX)
-
-
15,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

